Oliver Luxxe Assets LLC Acquires Shares of 18,573 IQVIA Holdings Inc. $IQV

Oliver Luxxe Assets LLC acquired a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 18,573 shares of the medical research company’s stock, valued at approximately $3,589,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Breakwater Capital Group increased its stake in shares of IQVIA by 3.2% during the second quarter. Breakwater Capital Group now owns 2,073 shares of the medical research company’s stock worth $401,000 after acquiring an additional 64 shares during the period. Community Trust & Investment Co. lifted its position in IQVIA by 5.0% in the second quarter. Community Trust & Investment Co. now owns 92,668 shares of the medical research company’s stock valued at $17,905,000 after purchasing an additional 4,388 shares during the period. Elevation Wealth Partners LLC lifted its position in IQVIA by 218.8% in the second quarter. Elevation Wealth Partners LLC now owns 153 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 105 shares during the period. Czech National Bank increased its position in IQVIA by 2.8% during the 2nd quarter. Czech National Bank now owns 47,506 shares of the medical research company’s stock worth $9,179,000 after purchasing an additional 1,316 shares during the period. Finally, PensionDanmark Pensionsforsikringsaktieselskab raised its stake in shares of IQVIA by 9.8% during the 2nd quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 30,122 shares of the medical research company’s stock worth $5,820,000 after buying an additional 2,700 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

IQV has been the topic of a number of analyst reports. Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Morgan Stanley reissued an “equal weight” rating and issued a $200.00 target price (down from $225.00) on shares of IQVIA in a report on Wednesday, June 17th. Robert W. Baird boosted their target price on shares of IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 29th. JPMorgan Chase & Co. upped their price target on shares of IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Finally, Deutsche Bank Aktiengesellschaft set a $240.00 price target on shares of IQVIA in a report on Thursday, July 9th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and a consensus price target of $241.88.

IQVIA Stock Performance

NYSE IQV opened at $237.97 on Friday. The business has a 50 day moving average price of $200.92 and a 200 day moving average price of $186.95. The company has a market capitalization of $39.17 billion, a P/E ratio of 29.53, a PEG ratio of 2.03 and a beta of 1.18. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $251.36. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The company had revenue of $4.37 billion for the quarter, compared to the consensus estimate of $4.30 billion. During the same period in the previous year, the business earned $2.81 earnings per share. IQVIA’s quarterly revenue was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Sell-side analysts expect that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA announced that its Board of Directors has approved a share repurchase plan on Thursday, May 7th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s board believes its shares are undervalued.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider W Richard Staub sold 5,500 shares of the firm’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the completion of the transaction, the insider directly owned 13,312 shares in the company, valued at approximately $3,097,436.16. This trade represents a 29.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Keriann Cherofsky sold 558 shares of IQVIA stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total transaction of $136,827.18. Following the transaction, the insider owned 2,989 shares of the company’s stock, valued at approximately $732,932.69. The trade was a 15.73% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 12,913 shares of company stock valued at $3,098,793 in the last quarter. Insiders own 1.70% of the company’s stock.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.